Your browser doesn't support javascript.
loading
Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
Crusoe, Edvan de Queiroz; Higashi, Fabiana; Martinez, Gracia; Bittencourt, Rosane; Pinto Neto, Jorge Vaz; Sousa, Lais; Santucci, Rodrigo; Magalhães, Roberto José Pessoa; Colli, Gilberto; Nunes, Renata Ferreira Marques; Ribeiro, Glaciano; Nicacio, Jandir; Zanella, Karla Richter; Kutner, José Mauro; Magalhaes, André; Leão, Danielle; Hallack Neto, Abrahão Elias; Braga, Walter; Souza, Emanuella G; Guimarães, Antonio Julio A. M; Durigon, Giovanna Steffenello; Laks, Dani; Maiolino, Angelo; Hungria, Vania Tietsche de Moraes.
Affiliation
  • Crusoe, Edvan de Queiroz; Universidade Federal da Bahia - UFBA. Hospital Universitário Professor Edgard Santos. Salvador. BR
  • Higashi, Fabiana; Irmandade da Santa Casa de Misericórdia de São Paulo. São Paulo. BR
  • Martinez, Gracia; Universidade de São Paulo - USP. Faculdade de Medicina. Hospital das Clinicas Instituto do Cancer. São Paulo. BR
  • Bittencourt, Rosane; Hospital de Clínicas de Porto Alegre. Porto Alegre. BR
  • Pinto Neto, Jorge Vaz; Centro de Câncer de Brasília. Brasília. BR
  • Sousa, Lais; Centro de Hematologia e Oncologia. Clínica CEHON. Salvador. BR
  • Santucci, Rodrigo; Instituto HEMOMED. São Paulo. BR
  • Magalhães, Roberto José Pessoa; Universidade Federal do Rio de Janeiro - UFRJ. Hospital Universitário Clementino Fraga Filho. Rio de Janeiro. BR
  • Colli, Gilberto; Hospital de Câncer de Barretos. Fundação Pio XII. Barretos. BR
  • Nunes, Renata Ferreira Marques; Hospital Brigadeiro. São Paulo. BR
  • Ribeiro, Glaciano; Clínica Hematológica. Belo Horizonte. BR
  • Nicacio, Jandir; Hospital de Base. São José do Rio Preto. BR
  • Zanella, Karla Richter; Clínica Viver - CEPON. Florianópolis. BR
  • Kutner, José Mauro; Hospital Israelita Albert Einstein. São Paulo. BR
  • Magalhaes, André; Centro de Hematologia e Oncologia. Clínica CEHON. Juazeiro. BR
  • Leão, Danielle; Universidade Federal de Goiás - UFG. Hospital das Clínicas de Goiás. Goiânia. BR
  • Hallack Neto, Abrahão Elias; Universidade Federal de Juiz de Fora - UFJF. Hospital Universitário. Juiz de Fora. BR
  • Braga, Walter; Universidade Federal de São Paulo - UNIFESP. São Paulo. BR
  • Souza, Emanuella G; Universidade Federal de Minas Gerais - UFMG. Hospital das Clínicas da Belo Horizonte. BR
  • Guimarães, Antonio Julio A. M; Hemorio. Rio de Janeiro. BR
  • Durigon, Giovanna Steffenello; Universidade Federal de Santa Catarina - UFSC. Santa Catarina. BR
  • Laks, Dani; Instituto de Hematologia. Porto Alegre. BR
  • Maiolino, Angelo; Universidade Federal do Rio de Janeiro - UFRJ. Hospital Universitário Clementino Fraga Filho. Rio de Janeiro. BR
  • Hungria, Vania Tietsche de Moraes; Clínica São Germano. São Paulo. BR
Hematol., Transfus. Cell Ther. (Impr.) ; 42(2): 118-124, Apr.-June 2020. tab, ilus
Article in En | LILACS | ID: biblio-1134012
Responsible library: BR408.1
Localization: BR408.1
ABSTRACT
ABSTRACT

Background:

The treatment of multiple myeloma (MM) has evolved significantly in the past decade, and new drug combinations have improved the response rates and prolonged survival. Studies comparing different induction chemotherapy regimens have shown that triple combinations have better results than double combinations. However, comparisons among different triple combinations are rare in the literature.

Methods:

We retrospectively compared two triple combinations comprising bortezomib, cyclophosphamide and dexamethasone (VCD) versus thalidomide, cyclophosphamide and dexamethasone (CTD), and aimed at identifying which of the two combinations would yield better response rates following four induction cycles prior to hematopoietic cell transplantation in patients with untreated multiple myeloma.

Results:

We retrospectively reviewed the medical records of 311 patients from 24 different centers.The VCD regimen was used as induction therapy by 117 (37.6%) patients, whereas 194 (62.4%) patients received the CTD regimen. After four cycles of induction on an intention-to-treat basis, 54% of the patients in the VCD group achieved at least very good partial response versus 42.8% in the CTD group (p = 0.05). We observed no difference in neuropathy or thrombotic events rates among the two regimens.

Conclusion:

Our results corroborate the superiority of the triple combination regimes containing bortezomib over the triple combination with thalidomide as pre ASCT induction therapy in MM.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: LILACS Main subject: Antineoplastic Combined Chemotherapy Protocols / Bone Marrow Transplantation / Bortezomib / Multiple Myeloma / Antineoplastic Agents Type of study: Diagnostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male Language: En Journal: Hematol., Transfus. Cell Ther. (Impr.) Journal subject: Hematologia / TransfusÆo de Sangue Year: 2020 Document type: Article Affiliation country: Brazil / Cuba Country of publication: Brazil

Full text: 1 Collection: 01-internacional Database: LILACS Main subject: Antineoplastic Combined Chemotherapy Protocols / Bone Marrow Transplantation / Bortezomib / Multiple Myeloma / Antineoplastic Agents Type of study: Diagnostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male Language: En Journal: Hematol., Transfus. Cell Ther. (Impr.) Journal subject: Hematologia / TransfusÆo de Sangue Year: 2020 Document type: Article Affiliation country: Brazil / Cuba Country of publication: Brazil